Jiangsu HengRui Medicine Co., Ltd.: Hyperuricemia trials
The registry lists 13 Hyperuricemia studies with Jiangsu HengRui Medicine Co., Ltd. as lead sponsor. 1 are open to participants now and 0 have results posted.
Phase 1 9Phase 2 4(a study in two phases counts in both)
Studies
Open to participants first, then studies with results posted, then the rest; newest registration first within each.
- The Efficacy and Safety of SHR4640 Tablet Combined With 40 mg Febuxostat Tablets in the Treatment of Primary Gout and HyperuricemiaRecruitingNCT07362355Phase 2
- PK Effects of SHR4640 on Repaglinide and Midazolam, and the Impact of SHR4640 on QT IntervalCompletedNCT06196580Phase 1
- Bioequivalence Study of 2 Sizes of SHR4640 Tablets Orally in Healthy SubjectsCompletedNCT06168929Phase 1
- Pharmacokinetic/Pharmacokinetic and Safety Studies of SHR4640 in Subjects With Moderate Renal Insufficiency and Healthy SubjectsCompletedNCT05954169Phase 1
- Clinical Study of SHR4640 Tablets Combined With Febuxostat Tablets in the Treatment of Primary Gout and HyperuricemiaStatus unknownNCT05513976Phase 2
- A Trial of HR091506 Tablets in Treatment of Primary Gout With Hyperuricemia in AdultsStatus unknownNCT05347498Phase 1
- Study on the Bioavailability of Three Different Prescription Processes of SHR4640 Tablets in Healthy VolunteersStatus unknownNCT04586803Phase 1
- A Safety and Efficacy Study of SHR4640 and Febuxostat in Subjects With HyperuricemiaStatus unknownNCT04180982Phase 2
- The Drug-Drug Interaction of SHR4640 and Febuxostat in Patients With HyperuricemiaStatus unknownNCT04157959Phase 1
- Multiple Doses Study of SHR4640 in Male Subjects With High Serum Uric Acid LevelCompletedNCT03211403Phase 1
- Dose-finding and Safety Study of SHR4640 in Subjects With HyperuricemiaCompletedNCT03185793Phase 2
- Multiple Dose Study of SHR4640 in Healthy SubjectsCompletedNCT02890966Phase 1
- Single Dose Study of SHR4640 in Healthy SubjectsCompletedNCT02815839Phase 1